...
首页> 外文期刊>The Journal of Allergy and Clinical Immunology >Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response.
【24h】

Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response.

机译:沙丁胺醇诱导的气道对变应原的反应性增强,与乙酰甲胆碱:剂量反应相比,保护作用降低。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Two adverse effects of inhaled beta 2-agonists are increased airway responsiveness to allergen and tolerance to the bronchoprotective effect of beta 2-agonists versus bronchoconstrictors (e.g., methacholine). OBJECTIVE: We studied three doses of inhaled salbutamol, 200, 400, and 800 micrograms/day, to determine dose-response curves for these two adverse effects. METHODS: Ten atopic patients with mild, stable asthma free of all asthma medications, allergen exposure, and respiratory tract infection for at least 4 weeks participated in a double-blind, random-order, crossover study. There were four 1-week treatment periods with a 1-week washout period: placebo, salbutamol 200 micrograms, 400 micrograms and 800 micrograms per day. After each treatment, we assessed FEV1, bronchodilation 10 minutes after administration of 200 micrograms of salbutamol, methacholine PC20, methacholine dose-shift after administration of 200 micrograms of salbutamol, and allergen PC20. RESULTS: There was no significant difference in baseline FEV1, bronchodilation, or methacholine PC20. The methacholine dose shift was maximum after the placebo (3.4 +/- 0.22 doubling doses) and was significantly greater (p < 0.01) than all salbutamol regimens (2.2 to 2.6), which were not significantly different from each other (p > 0.05). Allergen PC20 was significantly lower (p < 0.02) after salbutamol 800 micrograms/day (geometric mean = 288 protein nitrogen units [PNU]/ml) than each of the other treatments (447 to 550 PNU/ml), which were not significantly different from each other (p > 0.05). CONCLUSION: Significant increase in airway responsiveness to allergen occurred only with the largest dose of inhaled salbutamol (800 micrograms/d); however, tolerance to the acute bronchoprotective effect of salbutamol was observed with all the three salbutamol regimens, even 200 micrograms/day. This suggests different mechanisms may be operative in producing these two effects.
机译:背景:吸入的β2-激动剂的两个不利影响是气道对过敏原的反应性增强,以及对β2-激动剂和支气管收缩剂(例如,乙酰甲胆碱)的支气管保护作用的耐受性。目的:我们研究了吸入的沙丁胺醇的三种剂量,分别为200、400和800微克/天,以确定这两种不良反应的剂量反应曲线。方法:十名患有轻度,稳定型哮喘,无任何哮喘药物,过敏原暴露和呼吸道感染至少持续4周的特应性患者参加了一项双盲,随机,交叉研究。治疗分为四个1周治疗期和1周洗脱期:安慰剂,沙丁胺醇200微克,每天400微克和800微克。每次治疗后,我们评估FEV1,在200毫克沙丁胺醇,乙酰甲胆碱PC20施用后10分钟支气管扩张,在200毫克沙丁胺醇和过敏原PC20施用后乙酰甲胆碱剂量变化。结果:基线FEV1,支气管扩张或乙酰甲胆碱PC20无显着差异。乙酰甲胆碱的剂量变化在安慰剂后最大(3.4 +/- 0.22倍),并且比所有沙丁胺醇方案(2.2至2.6)显着更大(p <0.01),彼此之间无显着差异(p> 0.05) 。沙丁胺醇800微克/天(几何平均值= 288个蛋白质氮单位[PNU] / ml)后,变应原PC20显着低于(p <0.02),这与其他每种治疗方法(447至550 PNU / ml)没有显着差异彼此之间(p> 0.05)。结论:仅在吸入最大剂量沙丁胺醇(800微克/天)的情况下,气道对过敏原的反应性才显着增加。然而,在所有三种沙丁胺醇方案中均观察到对沙丁胺醇的急性支气管保护作用具有耐受性,甚至为200微克/天。这表明产生这两种作用的不同机制可能起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号